Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check11 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check32 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.3%
- Check61 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check69 days agoChange DetectedThe website has updated the contact details section for the study, clarifying who to contact for questions and providing information on the study's location, with a revision from v2.12.2 to v2.13.2.SummaryDifference3%
Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.